HABP2 and neoplasm: Representative viable and necrotic areas of HABP immunostained sections from 231_WT tumors in Figure 5a and 231_VEGF tumors in Figure 5b show decreased HABP immunostaining in viable tumor regions of VEGF overexpressing tumors, and in necrotic tumor regions.